2- ((3- ((4- ((5- (2- ((3- fluorophenyl)amino)- 2- oxoethyl)- 1H- pyrazol- 3- yl)amino)quinazolin- 7- yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate

Subscribe to Selected New Research on 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate

5 relevant articles (2 outcomes, 1 trials/studies) found for this Bio-Agent

Description: an aurora B kinase inhibitor; structure in first source

Also Known As:

AZD 1152; AZD-1152; AZD1152

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Organophosphorus Compounds: 126

Phosphoric Acid Esters: 278

2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate: 5

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Quinazolines: 16

2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate: 5

Experts

1.	Deutsch, E: 1 article (05/2008)
2.	Bourhis, J: 1 article (05/2008)
3.	Frascogna, V: 1 article (05/2008)
4.	Castedo, M: 1 article (05/2008)
5.	Tao, Y: 1 article (05/2008)
6.	Girdler, F: 1 article (05/2008)
7.	Zhang, P: 1 article (05/2008)
8.	Kroemer, G: 1 article (05/2008)
9.	Belch, Andrew R: 1 article (02/2008)
10.	Reiman, Tony: 1 article (02/2008)

Related Diseases

1.	Neoplasms (Cancer) 05/22/2008 - "Altogether, these data indicate that AZD1152 can radiosensitize tumor cell lines in vitro and in vivo, the fact that these effects are exacerbated in p53-deficient cancer cells is of potential interest for further clinical development." 03/01/2008 - "An intermediate but active dose of AZD1152 (12.5 mg/kg) produced a less significant increase in M30 plasma levels at day 5. It was also confirmed that the plasma profiles of M30 and M65 mirrored closely those measured in whole tumor lysates" 06/15/2007 - "EXPERIMENTAL DESIGN: The pharmacodynamic effects and efficacy of AZD1152 were determined in a panel of human tumor xenograft models" 06/15/2007 - "RESULTS: AZD1152 potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to > or =100%; P < 0.05) in immunodeficient mice" 05/22/2008 - "We evaluated the effects of the bona fide Aurora-B kinase inhibitor AZD1152 on tumor responses to ionizing radiation (IR)" Get all the results and reference details, order at left...
2.	Multiple Myeloma 02/01/2008 - "The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma." Get all the results and reference details, order at left...
3.	Leukemia 09/15/2007 - "The combined administration of AZD1152 and conventional chemotherapeutic agent to patients with leukemia warrants further investigation." 09/15/2007 - "Taken together, AZD1152 is a promising new agent for treatment of individuals with leukemia" 09/15/2007 - "The present study explored the effect of AZD1152, a highly selective inhibitor of Aurora B kinase, on various types of human leukemia cells" 09/15/2007 - "AZD1152 inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 nM to 40 nM, as measured by thymidine uptake on day 2 of culture" 09/15/2007 - "AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo." Get all the results and reference details, order at left...
4.	Acute Eosinophilic Leukemia 09/15/2007 - "AZD1152 inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 nM to 40 nM, as measured by thymidine uptake on day 2 of culture" Get all the results and reference details, order at left...
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/15/2007 - "AZD1152 inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 nM to 40 nM, as measured by thymidine uptake on day 2 of culture" Get all the results and reference details, order at left...
7 Diseases and 5 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	aurora kinase (aurora A kinase)
2.	Biological Markers (Surrogate Marker)
3.	Tubulin
4.	Thymidine
5.	Histones (Histone)
6.	Type II DNA Topoisomerases (Topoisomerase II)
7.	DNA (Deoxyribonucleic Acid)
8.	Antigens
8 Drugs and Important Bio-Agents and 5 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>